Clinical Trial Update: A Study of Tolerability and Safety of Two New Doses of Grass MATA MPL [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating tolerability and safety of two new doses of Grass MATA MPL for allergic rhinitis has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis

Drugs mentioned

• Grass MATA MPL (grass pollen extract with MPL adjuvant)

Snippet

Sponsor: Allergy Therapeutics | Conditions: Allergic Rhinitis | Phase 1 | Status: COMPLETED